CYP2C9 Activators

CYP2C9 Activators are chemicals that can enhance the functional activity of CYP2C9, a member of the cytochrome P450 superfamily. These activators are substrates that undergo biotransformation by CYP2C9, which, in turn, enhances its functional activity. For instance, Glipizide, a sulfonylurea, stimulates insulin production, and its metabolism by CYP2C9 can enhance the enzyme's functional activity. Similarly, the angiotensin II receptor antagonist Losartan is metabolized by CYP2C9 into its active metabolite, E-3174, a process that can enhance the functional activity of the enzyme. Other compounds like Fluvastatin, a statin, and Tolbutamide, a first-generation sulfonylurea, undergo biotransformation by CYP2C9, which can also enhance its functional activity.

Other notable CYP2C9 activators include Phenytoin, Warfarin, Celecoxib, and Irbesartan. Phenytoin, an anti-epileptic drug, is metabolized by CYP2C9, and this biotransformation stimulates the enzyme's functional activity. Warfarin, an anticoagulant, undergoes a similar metabolic process, which can also enhance CYP2C9's activity. Celecoxib, a COX-2inhibitor, and Irbesartan, an angiotensin II receptor antagonist, are also metabolized by CYP2C9, leading to an enhancement of its functional activity. The last group of notable CYP2C9 activators includes Piroxicam, Valsartan, Naproxen, and Ibuprofen, which all belong to the non-steroidal anti-inflammatory drug (NSAID) class. Each of these compounds is metabolized by CYP2C9, and this biotransformation process enhances the functional activity of the enzyme. For instance, Piroxicam's metabolism by CYP2C9 results in an enhancement of the enzyme's activity. Similarly, Valsartan, an angiotensin II receptor antagonist, undergoes metabolic transformation by CYP2C9, which leads to an increased enzyme activity. Lastly, Naproxen and Ibuprofen, both NSAIDs, are metabolized by CYP2C9, and these biotransformation processes contribute to the enhancement of CYP2C9's functional activity.